ARB vs. ACEI: Researchers Say Study Ends Debate Over Safety, Efficacy

This article originally appeared here.
ARB vs. ACEI: Researchers Say Study Ends Debate Over Safety, Efficacy
ARB vs. ACEI: Researchers Say Study Ends Debate Over Safety, Efficacy

HealthDay News — Angiotensin receptor blockers (ARBs) are just as effective and safe as angiotensin-converting enzyme inhibitors (ACEIs), according to research published in the January issue of the Mayo Clinic Proceedings.

Sripal Bangalore, MD, of the Leon H. Charney Division of Cardiology at the New York University School of Medicine in New York City, and colleagues reviewed 106 randomized trials involving 254 301 patients to examine the effects of ARBs and ACEIs.

Although ACEIs were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACEIs have greater benefits. According to the new analysis, the only difference between the medications is that ARBs are more easily tolerated.

"There has been debate for many years over the safety and efficacy of ACE inhibitors compared to ARBs, with many of them using an 'ACE inhibitor-first' approach, with ARBs regarded as less effective," Bangalore said in a NYU Langone Medical Center news release. "We believe that our study ends the debate and gives physicians the option to prescribe either drug for their patients."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Loading links....